.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This prospective, multicentre randomized trial evaluated whether middle meningeal artery embolization (MMAE) combined with surgical evacuation reduced recurrence or progression of symptomatic subacute or chronic subdural hematoma compared with surgery alone in 400 patients. Participants were randomized to embolization plus surgery (n=197) or surgery alone (n=203), with the primary endpoint being hematoma recurrence or progression requiring repeat surgery within 90 days. Repeat surgery was required in 8 patients (4.1%) in the embolization group compared with 23 (11.3%) in the control group, corresponding to a relative risk of 0.36 (95% CI, 0.11–0.80; P=0.008) and an absolute reduction of 7.2 percentage points. Neurological deterioration at 90 days occurred in 11.9% versus 9.8%, respectively, yielding a risk difference of 2.1 percentage points (95% CI, −4.8 to 8.9). Mortality at 90 days was 5.1% with embolization and 3.0% with surgery alone. Serious procedure-related adverse events occurred in 4 patients (2.0%) in the embolization group by 30 days, including 2 disabling strokes; no additional such events occurred by 180 days. Adjunctive MMAE reduced the need for repeat surgery, although further assessment of procedure-related risks and longer-term safety remains important
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This prospective, multicentre randomized trial evaluated whether middle meningeal artery embolization (MMAE) combined with surgical evacuation reduced recurrence or progression of symptomatic subacute or chronic subdural hematoma compared with surgery alone in 400 patients. Participants were randomized to embolization plus surgery (n=197) or surgery alone (n=203), with the primary endpoint being hematoma recurrence or progression requiring repeat surgery within 90 days. Repeat surgery was required in 8 patients (4.1%) in the embolization group compared with 23 (11.3%) in the control group, corresponding to a relative risk of 0.36 (95% CI, 0.11–0.80; P=0.008) and an absolute reduction of 7.2 percentage points. Neurological deterioration at 90 days occurred in 11.9% versus 9.8%, respectively, yielding a risk difference of 2.1 percentage points (95% CI, −4.8 to 8.9). Mortality at 90 days was 5.1% with embolization and 3.0% with surgery alone. Serious procedure-related adverse events occurred in 4 patients (2.0%) in the embolization group by 30 days, including 2 disabling strokes; no additional such events occurred by 180 days. Adjunctive MMAE reduced the need for repeat surgery, although further assessment of procedure-related risks and longer-term safety remains important
Today
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
5 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
6 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
6 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
6 days back
